Sinovac Biotech (NASDAQ:SVA – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $1.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $6.00. HC Wainwright’s target price would suggest a potential downside of 84.54% from the company’s current price.
Sinovac Biotech Price Performance
Shares of SVA remained flat at $6.47 during trading hours on Tuesday. The business has a 50-day moving average of $6.47 and a 200 day moving average of $6.47. The company has a quick ratio of 5.97, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. Sinovac Biotech has a 12-month low of $5.73 and a 12-month high of $8.75.
Institutional Investors Weigh In On Sinovac Biotech
Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in shares of Sinovac Biotech in the second quarter valued at approximately $38,000. California Public Employees Retirement System acquired a new stake in Sinovac Biotech during the 2nd quarter worth approximately $445,000. Finally, Geode Capital Management LLC bought a new stake in Sinovac Biotech in the 2nd quarter valued at $179,000.
About Sinovac Biotech
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine.
Read More
- Five stocks we like better than Sinovac Biotech
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
- AI Is Making Cybersecurity Harder to Ignore—These 3 ETFs Offer a Broad Bet
- Campbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to Deliver
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
